---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-013644"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T05:55:24.983223+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Dyadic Q1 revenue up 50.9% YoY to $978K; net loss narrows to $956K

## Summary
- Revenue of $978K (+50.9% YoY); net loss $(0.03)/share vs $(0.09) prior year.
- Cash and securities $11.8M at Mar 31, 2023, down from $12.7M at Dec 31, 2022.
- Received ~$1.27M from sale of minority stake in Alphazyme in Jan 2023.
- DYAI-100 booster vaccine dosing completed; no serious adverse events; safety report due June 2023.
- Expanded collaborations with Rubic One Health (Africa) and new top-5 pharma research.

## SEC filing metadata
- accession: 0001437749-23-013644
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000143774923013644/0001437749-23-013644-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000143774923013644/dyai20230125_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-013644
- JSON: https://secwatch.observer/filing/0001437749-23-013644.json
- Plain text: https://secwatch.observer/filing/0001437749-23-013644.txt

## Key facts
- Earnings Releases
  DYADIC INTERNATIONAL INC reported financial results for quarter ended March 31, 2023.
  - Period: quarter ended March 31, 2023
  - Result: reported results
  source text: Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced its financial results for the first quarter of 2023, and highlighted recent company developments.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1213809/000143774923013644/0001437749-23-013644-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.